1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/20708
Full metadata record
DC FieldValueLanguage
dc.contributor.authorEconomou, M.en
dc.contributor.authorManolakopoulos, S.en
dc.contributor.authorTrikalinos, T. A.en
dc.contributor.authorFilis, S.en
dc.contributor.authorBethanis, S.en
dc.contributor.authorTzourmakliotis, D.en
dc.contributor.authorAvgerinos, A.en
dc.contributor.authorRaptis, S.en
dc.contributor.authorTsianos, E. V.en
dc.date.accessioned2015-11-24T19:09:30Z-
dc.date.available2015-11-24T19:09:30Z-
dc.identifier.issn1007-9327-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/20708-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAlanine Transaminase/blooden
dc.subjectAntiviral Agents/metabolism/*therapeutic useen
dc.subjectDNA, Viral/blooden
dc.subject*Drug Therapy, Combinationen
dc.subjectGenotypeen
dc.subjectHepatitis B e Antigens/*immunologyen
dc.subjectHepatitis B, Chronic/*drug therapy/geneticsen
dc.subjectHumansen
dc.subjectInterferon-alpha/adverse effects/metabolism/*therapeutic useen
dc.subjectLamivudine/metabolism/*therapeutic useen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectReverse Transcriptase Inhibitors/metabolism/*therapeutic useen
dc.subjectTreatment Outcomeen
dc.titleInterferon-alpha plus lamivudine vs lamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis Ben
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/16270403-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2005-
heal.abstractAIM: The HBeAg negative form of chronic hepatitis B (CHB) predominates in the Mediterranean area and has a rising frequency in Europe and North America. At present there are three approved therapies for patients with CHB: interferon-alpha (IFN-alpha), lamivudine and adefovir dipivoxil. Unfortunately, none of these drugs are effective in achieving a sustained response in patients with HBeAg negative CHB. Therefore, new therapeutic approaches have been examined. Our aim was to investigate the efficacy of combination treatment of IFN-alpha and lamivudine compared to lamivudine monotherapy, after 24 mo of administration in HBeAg-negative hepatitis B patients. METHODS: Fifty consecutive patients were randomly assigned to receive IFN-alpha-2b (5 MU thrice per week, n = 24) plus lamivudine (100 mg daily) or lamivudine only (n = 26) for 24 mo. Patients were followed up for further 6 mo. The primary outcome was the proportion with sustained virological response (undetectable serum HBV DNA concentrations) and or sustained biochemical response (transaminase levels within normal range) at 30 mo (6 mo after the end of therapy). Secondary end-points were timed from initial virological (biochemical) response to VBR (BBR, respectively) and the emergence of YMDD mutants across the two arms. RESULTS: Five of twenty-four (21%) patients in the combination arm vs 3/26 (12%) in the lamivudine arm had sustained response (i.e., normal serum transaminase levels and undetectable HBV DNA by PCR assay) 6 mo after treatment discontinuation. A reduction in the emergence of YMDD mutants and in the development of virological breakthroughs was observed in patients receiving combination treatment (10% vs 46%, P = 0.01 and 14% vs 46%, P = 0.03, respectively). Time from initial virologic response to virologic breakthrough (VBR) was greater among initial responders receiving combination treatment compared to those receiving lamivudine (22.9 mo vs 15.9 mo, respectively; P = 0.005). CONCLUSION: Our results demonstrate that IFN-alpha plus lamivudine combination therapy did not increase the sustained response, compared to lamivudine. However, combination therapy reduces the likelihood of VBR due to YMDD mutants and prolongs the time period until the breakthrough development.en
heal.journalNameWorld J Gastroenterolen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
File Description SizeFormat 
Tsianos-2005-interferon a plus.pdf217.28 kBAdobe PDFView/Open    Request a copy
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons